India is processing Oman’s request for hydroxychloroquine (HCQ) tablets for treatment of Novel Coronavirus (COVID-19) patients.
Speaking exclusively to Muscat Daily from New Delhi, a source in the Indian government said, “We are processing the request to send 10 lakh [1mn] HCQ tablets to Oman. The request is being processed at the highest level.”
India is the world’s largest manufacturer of the anti-malarial drug that is being touted as key in the fight against the COVID-19 pandemic. HCQ is widely used for treatment of rheumatoid arthritis, malaria and lupus.
“There is enough stock of hydroxychloroquine in the country [India]. We are tracking its demand, availability and production on a daily basis,” Shubhra Singh, chairperson, India’s National Pharmaceutical Pricing Authority, told news agency Press Trust of India.
Earlier, India had cleared the export of the drug to the US, Spain, Germany, Bahrain, Brazil, Nepal, Bhutan, Afghanistan, Maldives, Bangladesh, Seychelles, Mauritius and the Dominican Republic.